Therapeutic Efficacy of p53 Restoration in Mdm2-Overexpressing Tumors
暂无分享,去创建一个
Peirong Yang | Yun Zhang | G. Lozano | J. Jackson | S. Xiong | Qin Li | G. Chau | A. El-Naggar
[1] V. Pant,et al. The p53–Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity , 2013, Genes & development.
[2] Anil K Sood,et al. Poor survival with wild-type TP53 ovarian cancer? , 2013, Gynecologic oncology.
[3] Barbara Costa,et al. Human Glioblastoma Multiforme: p53 Reactivation by a Novel MDM2 Inhibitor , 2013, PloS one.
[4] Stine H. Kresse,et al. Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma , 2013, Cancer.
[5] W. El-Deiry,et al. p21WAF1 and tumourigenesis: 20 years after , 2013, Current opinion in oncology.
[6] Guillermina Lozano,et al. Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy , 2012, Clinical Cancer Research.
[7] Drew M. Lowery,et al. AATF/Che‐1 acts as a phosphorylation‐dependent molecular modulator to repress p53‐driven apoptosis , 2012, The EMBO journal.
[8] V. Baladandayuthapani,et al. Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA , 2012, Molecular Cancer Therapeutics.
[9] A. E. Silva,et al. Alterations of the TP53 Gene in Gastric and Esophageal Carcinogenesis , 2012, Journal of biomedicine & biotechnology.
[10] Thelma Thompson,et al. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization , 2012, Proceedings of the National Academy of Sciences.
[11] J. Blay,et al. A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors. , 2012 .
[12] L. Vassilev,et al. Pharmacodynamic Biomarkers in the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia , 2011 .
[13] C. Michiels,et al. Reciprocal influence of the p53 and the hypoxic pathways , 2011, Cell Death and Disease.
[14] Bin Bao,et al. Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors , 2011, Oncotarget.
[15] C. Maki,et al. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3 , 2011, Oncogene.
[16] A. El‐Naggar,et al. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. , 2011, The Journal of clinical investigation.
[17] G. Lozano,et al. Regulation of tissue‐ and stimulus‐specific cell fate decisions by p53 in vivo , 2011, The Journal of pathology.
[18] L. Vassilev,et al. A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL) , 2010 .
[19] E. Brambilla,et al. The ARF tumor suppressor: Structure, functions and status in cancer , 2010, International journal of cancer.
[20] Arnold J Levine,et al. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development. , 2010, Cancer cell.
[21] J. Manfredi. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. , 2010, Genes & development.
[22] P. Ouillette,et al. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. , 2010, Blood.
[23] I. Okayasu,et al. Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face. , 2010, Human pathology.
[24] Jeremy R Stuart,et al. Low-Dose Radiation-Induced Senescent Stromal Fibroblasts Render Nearby Breast Cancer Cells Radioresistant , 2009, Radiation research.
[25] Patricia Greninger,et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. , 2009, Cancer cell.
[26] G. Lozano,et al. Mdm4 loss in the intestinal epithelium leads to compartmentalized cell death but no tissue abnormalities. , 2009, Differentiation; research in biological diversity.
[27] J. Baselga,et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of HDM-2 antagonist JNJ-26854165 in patients with advanced refractory solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] G. Evan,et al. Modelling Myc inhibition as a cancer therapy , 2008, Nature.
[29] H. Okano,et al. The intestinal epithelium compensates for p53-mediated cell death and guarantees organismal survival , 2008, Cell Death and Differentiation.
[30] Guillermina Lozano,et al. Mdm2 and Mdm4 Loss Regulates Distinct p53 Activities , 2008, Molecular Cancer Research.
[31] T. Iwakuma,et al. The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. , 2008, Genes & development.
[32] C. Blattner,et al. JNJ-26854165 - a novel hdm2 antagonist in clinical development showing broad-spectrum preclinical antitumor activity against solid malignancies , 2008 .
[33] Dajun Yang,et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.
[34] D. Notterman,et al. MDM2 Gene Amplification Is Correlated to Tumor Progression but not to the Presence of SNP309 or TP53 Mutational Status in Primary Colorectal Cancers , 2008, Molecular Cancer Research.
[35] D. Vaux,et al. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans , 2008, Cell Death and Differentiation.
[36] Guillermina Lozano,et al. Loss of Mdm4 Results in p53-Dependent Dilated Cardiomyopathy , 2007, Circulation.
[37] M. Olivier,et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.
[38] G. Lozano,et al. Haploinsufficiency of Mdm2 and Mdm4 in Tumorigenesis and Development , 2007, Molecular and Cellular Biology.
[39] T. Jacks,et al. Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.
[40] Carlos Cordon-Cardo,et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.
[41] Gerard I. Evan,et al. Modeling the Therapeutic Efficacy of p53 Restoration in Tumors , 2006, Cell.
[42] G. Wahl,et al. Mouse Mutants Reveal that Putative Protein Interaction Sites in the p53 Proline-Rich Domain Are Dispensable for Tumor Suppression , 2006, Molecular and Cellular Biology.
[43] G. Wahl,et al. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas , 2006, Nature Reviews Cancer.
[44] G. Evan,et al. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. , 2006, Cancer cell.
[45] A. Vercelli,et al. High Levels of Cre Expression in Neuronal Progenitors Cause Defects in Brain Development Leading to Microencephaly and Hydrocephaly , 2006, The Journal of Neuroscience.
[46] M. Dai,et al. Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc. , 2006, Neoplasia.
[47] Hiroyuki Yamamoto,et al. Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells , 2006, Journal of Medical Genetics.
[48] M. Kitayner,et al. Structural basis of DNA recognition by p53 tetramers. , 2006, Molecular cell.
[49] Su Qiu,et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. , 2006, Journal of medicinal chemistry.
[50] G. Wahl,et al. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. , 2006, Cancer cell.
[51] G. Wahl,et al. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4 , 2006, Cell Death and Differentiation.
[52] Geng-Hung Liu,et al. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[53] Antonina Andreeva,et al. Core domain interactions in full-length p53 in solution , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[54] D. Parks,et al. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo , 2006, Molecular Cancer Therapeutics.
[55] A. Fersht,et al. Comparative binding of p53 to its promoter and DNA recognition elements. , 2005, Journal of molecular biology.
[56] A. Bocian,et al. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in liver cirrhosis and hepatocellular carcinoma. , 2005, Journal of experimental & clinical cancer research : CR.
[57] L. Strong,et al. Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.
[58] M. Protopopova,et al. Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors , 2004, Nature Medicine.
[59] Patrick Dowd,et al. The ubiquitin ligase COP1 is a critical negative regulator of p53 , 2004, Nature.
[60] C. Cordon-Cardo,et al. MDM2 and prognosis. , 2004, Molecular cancer research : MCR.
[61] T. Hupp,et al. The Proline Repeat Domain of p53 Binds Directly to the Transcriptional Coactivator p300 and Allosterically Controls DNA-Dependent Acetylation of p53 , 2003, Molecular and Cellular Biology.
[62] Michael Berger,et al. Apoptosis - the p53 network , 2003, Journal of Cell Science.
[63] Guillermina Lozano,et al. Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation , 2003, Cell.
[64] T. Greiner,et al. Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis , 2003, The EMBO journal.
[65] C. Fenoglio-Preiser,et al. TP53 and gastric carcinoma: A review , 2003, Human mutation.
[66] S. Murray,et al. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response , 2002, Nature.
[67] S. Volinia,et al. The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults , 2002, Nature.
[68] K. Helin,et al. Mdm4 (Mdmx) Regulates p53-Induced Growth Arrest and Neuronal Cell Death during Early Embryonic Mouse Development , 2002, Molecular and Cellular Biology.
[69] Xin Lu,et al. Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.
[70] C. Harris,et al. The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.
[71] Andrew P McMahon,et al. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. , 2002, Developmental biology.
[72] D. Troyer,et al. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties. , 2002, Cancer research.
[73] T. Sugai,et al. p53 gene mutation and MDM2 overexpression in a case of primary malignant fibrous histiocytoma of the jejunum , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[74] R. Iggo,et al. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[75] S. Korsmeyer,et al. Bax Loss Impairs Myc-Induced Apoptosis and Circumvents the Selection of p53 Mutations during Myc-Mediated Lymphomagenesis , 2001, Molecular and Cellular Biology.
[76] A. Berns,et al. Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[77] A. El‐Naggar,et al. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2 , 2001, Oncogene.
[78] M. Murphy,et al. The Corepressor mSin3a Interacts with the Proline-Rich Domain of p53 and Protects p53 from Proteasome-Mediated Degradation , 2001, Molecular and Cellular Biology.
[79] P. Chène,et al. The role of tetramerization in p53 function , 2001, Oncogene.
[80] L. Donehower,et al. Is p53 Haploinsufficient for Tumor Suppression? Implications for the p53+/- Mouse Model in Carcinogenicity Testing , 2001, Toxicologic pathology.
[81] D. Wiederschain,et al. Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. , 2000, The American journal of pathology.
[82] B. Wasylyk,et al. MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis , 2000, The EMBO journal.
[83] N. Little,et al. Hdmx stabilizes Mdm2 and p53. , 2000, The Journal of biological chemistry.
[84] Mong-Hong Lee,et al. Association of the Cyclin-dependent Kinases and 14-3-3 Sigma Negatively Regulates Cell Cycle Progression* , 2000, The Journal of Biological Chemistry.
[85] R. Schneider-Stock,et al. Mdm2 Gene Amplification in Gastric Cancer Correlation with Expression of Mdm2 Protein and p53 Alterations , 2000, Modern Pathology.
[86] T. Koyama,et al. MDM2 Overexpression with Alteration of the p53 Protein and Gene Status in Oral Carcinogenesis , 2000, Japanese journal of cancer research : Gann.
[87] V. Zoumpourlis,et al. Altered Expression of the Cell Cycle Regulatory Molecules pRb, p53 and MDM2 Exert a Synergetic Effect on Tumor Growth and Chromosomal Instability in Non-small Cell Lung Carcinomas (NSCLCs) , 2000, Molecular medicine.
[88] D. Troyer,et al. Genetic determinants of response to chemotherapy in transgenic mouse mammary and salivary tumors , 2000, Oncogene.
[89] M. Jackson,et al. MdmX Protects p53 from Mdm2-Mediated Degradation , 2000, Molecular and Cellular Biology.
[90] I. Ganly,et al. p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy , 2000, British Journal of Cancer.
[91] G. Semenza,et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.
[92] G. Wahl,et al. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses , 1999, Oncogene.
[93] T. McDonnell,et al. Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice , 1999, The Journal of pathology.
[94] C. Harris,et al. GADD45 induction of a G2/M cell cycle checkpoint. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[95] D. Felsher,et al. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[96] B. Wasylyk,et al. MDM2 overexpression generates a skin phenotype in both wild type and p53 null mice , 1999, Oncogene.
[97] L. Donehower,et al. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[98] L. Hengst,et al. Effects of p21Cip1/Waf1 at Both the G1/S and the G2/M Cell Cycle Transitions: pRb Is a Critical Determinant in Blocking DNA Replication and in Preventing Endoreduplication , 1998, Molecular and Cellular Biology.
[99] Hirofumi Tanaka,et al. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 , 1997, FEBS letters.
[100] G. Chu. Double Strand Break Repair* , 1997, The Journal of Biological Chemistry.
[101] D. Lane,et al. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding , 1997, Oncogene.
[102] S. Berger,et al. CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. , 1997, Cancer research.
[103] J. Landers,et al. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. , 1997, Cancer research.
[104] Wenyi Wei,et al. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. , 1997, Science.
[105] H. Sakamoto,et al. Effect of Phosphorylation on Tetramerization of the Tumor Suppressor Protein p53 , 1997, Journal of protein chemistry.
[106] Wei Gu,et al. Synergistic activation of transcription by CBP and p53 , 1997, Nature.
[107] G. Lozano,et al. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. , 1997, Genes & development.
[108] S. Lowe,et al. Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.
[109] A. Levine,et al. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[110] A. Levine,et al. Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.
[111] D. Spandidos,et al. A MOLECULAR AND IMMUNOHISTOCHEMICAL STUDY OF THE MDM2 PROTEIN ISOFORMS AND p53 GENE PRODUCT IN BRONCHOGENIC CARCINOMA , 1996, The Journal of pathology.
[112] A. Jochemsen,et al. MDMX: a novel p53‐binding protein with some functional properties of MDM2. , 1996, The EMBO journal.
[113] W. Hong,et al. Retrovirus–mediated wild–type P53 gene transfer to tumors of patients with lung cancer. , 1996, Nature Medicine.
[114] K. Vousden,et al. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function , 1996, Molecular and cellular biology.
[115] K. Kinzler,et al. Genetic determinants of p53-induced apoptosis and growth arrest. , 1996, Genes & development.
[116] D. Haines,et al. Analysis of p53 and mdm‐2 expression in 18 patients with Sézary syndrome , 1996, British journal of haematology.
[117] Guillermina Lozano,et al. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.
[118] S. Elledge,et al. Inhibition of cyclin-dependent kinases by p21. , 1995, Molecular biology of the cell.
[119] T. Kinoshita,et al. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. , 1994, Blood.
[120] G. Wahl,et al. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. , 1994, Genes & development.
[121] J. Roth,et al. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. , 1994, Journal of the National Cancer Institute.
[122] M. Oren,et al. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. , 1994, Genes & development.
[123] R. Weinberg,et al. Tumor spectrum analysis in p53-mutant mice , 1994, Current Biology.
[124] T. Halazonetis,et al. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. , 1993, The EMBO journal.
[125] C. Pabo,et al. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. , 1993, Genes & development.
[126] C. Purdie,et al. Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.
[127] Bert Vogelstein,et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.
[128] Scott W. Lowe,et al. p53 is required for radiation-induced apoptosis in mouse thymocytes , 1993, Nature.
[129] P. Friedman,et al. The p53 protein is an unusually shaped tetramer that binds directly to DNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[130] E. White,et al. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. , 1993, Genes & development.
[131] M. Kastan,et al. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[132] P. Meltzer,et al. Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.
[133] A. Levine,et al. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. , 1992, Genes & development.
[134] K. Kinzler,et al. Definition of a consensus binding site for p53 , 1992, Nature Genetics.
[135] A. Kimchi,et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.
[136] K. Kinzler,et al. Identification of p53 as a sequence-specific DNA-binding protein , 1991, Science.
[137] D. George,et al. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. , 1991, The EMBO journal.
[138] L. Strong,et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.
[139] F. Collins,et al. Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.
[140] M. Oren,et al. Wild-type p53 can inhibit oncogene-mediated focus formation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[141] L. Kaczmarek,et al. Growth-dependent expression of human Mr 53,000 tumor antigen messenger RNA in normal and neoplastic cells. , 1986, Cancer research.
[142] V. Rotter,et al. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation , 1984, Nature.
[143] L. Old,et al. Microinjection of monoclonal antibody to protein p53 inhibits serum-induced DNA synthesis in 3T3 cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[144] F. McCormick,et al. Lymphocyte stimulation: concanavalin A induces the expression of a 53K protein. , 1980, Cell biology international reports.
[145] P. May,et al. Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum , 1979, Journal of virology.
[146] M. Martin,et al. Identification and partial characterization of new antigens from simian virus 40-transformed mouse cells , 1979, Journal of virology.
[147] D. Lane,et al. T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.
[148] J. Marine. MDM2 and MDMX in cancer and development. , 2011, Current topics in developmental biology.
[149] L. Vassilev,et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[150] David P. Lane,et al. Translating p53 into the clinic , 2010, Nature Reviews Clinical Oncology.
[151] R. Eisenman,et al. Tumor suppression and normal aging in mice with constitutively high p53 activity. , 2006, Genes & development.
[152] A. Multani,et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice , 2004, Nature Genetics.
[153] A. Levine,et al. A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.
[154] K. Aldape,et al. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[155] J. Bourhis,et al. British Journal of Cancer , 2001 .
[156] K. Ishak,et al. Sporadic and Thorotrast-induced angiosarcomas of the liver manifest frequent and multiple point mutations in K-ras-2. , 1997, Laboratory investigation; a journal of technical methods and pathology.
[157] C. Bellamy,et al. p53 and apoptosis. , 1997, British medical bulletin.
[158] J. Roth,et al. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. , 1993, Human gene therapy.
[159] V. Rotter,et al. Inhibition of cell growth mediated by plasmids encoding p53 anti-sense. , 1987, Oncogene.